# Greenwich LifeSciences (GLSI) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/GLSI
## Company Profile
- Ticker: GLSI
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biologics, Biopharma, Vaccines, Cancer Peptide Vaccines, Tumor Synthetic Peptide Vaccines
## Stock Data
- Close: 16.32 USD
- Market cap: 290628518.40000004 USD
- Last updated: 2026-07-17
## Business Overview
Greenwich LifeSciences is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
## Why The Stock Is Moving

GLSI is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Greenwich LifeSciences is followed within the biotech universe for its exposure to catalyst-driven execution.

## Business Model

Greenwich LifeSciences follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.

## Landscape Position

Compared with more mature healthcare peers, Greenwich LifeSciences sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 10:00 EST — [Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01-99f074c4) — Source: Greenwich LifeSciences
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck